Asymptomatic Septal Mass by Arden, Richard L et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Otolaryngology Articles Otolaryngology - Head and Neck Surgery 
2-1-2018 
Asymptomatic Septal Mass. 
Richard L. Arden 
Zachary H. Griggs 
Henry Ford Health System, ZGRIGGS1@hfhs.org 
Elizabeth A. Wey 
Follow this and additional works at: https://scholarlycommons.henryford.com/otolaryngology_articles 
Recommended Citation 
Arden RL, Griggs ZH, and Wey EA. Asymptomatic Septal Mass JAMA Otolaryngol Head Neck Surg 2018 
Feb 1;144(2):169-170. 
This Article is brought to you for free and open access by the Otolaryngology - Head and Neck Surgery at Henry 
Ford Health System Scholarly Commons. It has been accepted for inclusion in Otolaryngology Articles by an 
authorized administrator of Henry Ford Health System Scholarly Commons. 
Asymptomatic Septal Mass
Richard L. Arden, MD; Zachary H. Griggs, DO; Elizabeth A. Wey, MD
Awoman in her 40s presented with a 2-month history of a slowly enlarging, asymptom-
atic anterior septalmass. Shedeniedahistoryof localized trauma, substanceabuse, orprior
endonasal surgery. Examination revealedanontender, 8-mm,pink-red, soft, fleshygrowth
just posterior to themembranous septumnear the nostril apex. Histopathological analysis
demonstrated a well-circumscribed submucosal lesion comprised of bland, round, syncy-
tial cells, arranged in a concentric fashion around variably sized slit-like vascular spaces, a
minority of which were staghorn in appearance (Figure, A-C). No significant perivascular
hyalinizationwas identified.Theoverlyingnasalmucosaandsurroundingsubmucosalglands
were unremarkable. Immunohistochemical stains demonstrate the cellular population to
bestronglypositive for smooth-muscleactin (SMA),muscle-specificactin, andCD34(Figure,
D), but negative for B-catenin and epithelial membrane antigen.
Diagnosis
D.Myopericytoma
Discussion
ThenewWorldHealthOrganization (WHO)classificationof soft tis-
sue tumors (previously reported in 2002)wasupdated in 2013 and
now acknowledges thatmyofibroma and/ormyofibromatosis rep-
resents morphological points along the spectrum of myopericytic
neoplasms.1 Myopericytoma (MPC) is a mesenchymal tumor de-
rived fromtheperivascularmyoidcell, sharing featureswithsmooth-
muscleandglomuscells.2Previouslyencompassedunder thebroad
categoryof hemangiopericytomas, theseperivascularmyomas can
Original magnification ×20A Original magnification ×100B
Original magnification ×400C Original magnification ×100D
Figure.Histopathology of
asymptomatic septal mass shows (A)
a well-circumscribed, unencapsulated
lesion based in the submucosa with
an intact overlaying squamous and
respiratory mucosa
(hematoxylin-eosin); (B) bland,
vaguely spindled cells arranged
around prominent thin-walled vessels
with a “staghorn” branching
configuration (hematoxylin-eosin);
(C) the lesional cells are oval to
spindle shaped with abundant
cytoplasm and ill-defined cell borders
(hematoxylin-eosin); (D) the lesional
cells are stained diffusely with myoid
markers, including smoothmuscle
actin andmuscle-specific actin
(muscle-specific actin stain).
WHAT IS YOURDIAGNOSIS?
A. Glomus tumor
B. Myofibroma
C. Solitary fibrous tumor
D. Myopericytoma
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be categorized based on the predominant histologic pattern:myo-
fibromatosis, glomangiopericytoma, and myopericytoma.3 Ulti-
mately,diagnosis isbasedonthesecharacteristicmorphological fea-
turesandsupportive immunohistochemistry, recognizing that some
overlap exists with the exception of glomangiopericytoma, which
is histologically distinct and occurs in the sinonasal region.
Myopericytoma occursmainly in childhood tomid-adult years
with a male predominance and predilection for dermal and subcu-
taneous locations in the lowerextremities.Of the roughly 15.0%that
occur in the head and neck, only 2.5% are represented in the nose
andparanasal sinuses, accounting for less than 1.0%of sinonasal tu-
mors overall.4 This typically benign, slowly growing neoplasm, of-
tenpresents as a solitarypainlessmass that can causeepistaxis and
nasalobstruction.Onexamination, the lesionappearsnodular topol-
ypoid, soft and fleshy, friable, circumscribed, possesses a gray-pink
to beefy red color, and can bemistaken for an inflammatory polyp.
Myopericytoma arewell circumscribed (usually <2 cm) but un-
encapsulatedneoplasmswithblandandrelativelymonomorphicoval
to spindle-shaped cells that are arranged in a concentric or whor-
lingperivascularpattern.Theydiffer fromglomuscellsby their larger
size,moreabundantcytoplasm,and lackofaclearlydemarcatedcell
border.2 Immunostaining ischaracteristically strong forvimentinand
SMA expression but limited to small vessels for CD34.3,5 Pericytes
areSMApositive. Staining is characteristically negative forEMA, cy-
tokeratins, and usually desmin. By contrast, the rare sinonasal soli-
tary fibrous tumorexhibits apatternlessproliferationof spindlecells
admixed with variable amounts of ropy keloidal collagen, in-
creased perivascular and stromal collagen, haphazardly arranged
cells, and thin-walled vascular spaces. Strong diffuse immunoreac-
tivity for CD34 and CD99 is seen, with variably positive to absent
SMA expression.3,4,6 Unlike MPC, perivascular concentric growth
with accentuated perivenule myoid proliferation is not a promi-
nent feature of myofibroma. Diagnosis of myofibroma is typically
based on a characteristic biphasic zonal architecture with peri-
cytoid and myoid features, whose whorled multiple nodules may
displayprominent stromal hyalinization. Similar toMPC, glomus tu-
mor (GT) is apericyticneoplasmwith immunoreactivity for smooth-
muscleandmuscle-specificactin,aswellasusualnegativity forCD34.
However, these are very rare in the sinonasal region, and classic GT
ismorphologically composedof compact, uniform,polyhedral, epi-
thelioid cells organized in sheets, nests, or cords, andusually donot
possess staghorn-like vessel proliferation.7 Admittedly, it is recog-
nizedthatGT,particularlyvariantsofGT(eg,glomangiomyoma),may
overlapwithMPCand that clear distinctionmaynot always bepos-
sible. In the past, most myopericytic neoplasms lacked well-
defined genetic abnormalities, impeding their objective classifica-
tion; however, recent studies have identified recurrent gene
abnormalities, including SRF-RELA fusions amonga subset of cellu-
lar variant myofibromas andmyopericytomas8 and fusions involv-
ing members of the NOTCH family among GTs.9 These and future
genetic discoverieswill hopefully clarify the relationship among the
different myopericytic tumors and improve upon the current mor-
phologic classification.
Standard treatment forMPC is complete local resection,which
prognostically has provenmore important than tumor size or loca-
tion.Despite this, local recurrence rateshavebeen reportedat 10%
to 20%4,7 and likely related to incomplete excision and deep soft
tissue lesions. While the vast majority of these neoplasms are be-
nign with excellent prognosis, cases of malignant MPC have been
reported.10 Markers for poor prognosis and increased recurrence
rates (local and metastatic) include prominent mitotic activity (>4
of 10 per high-powered field), Ki-67 proliferation index greater
than 10%, focal necrosis, cellular atypia, and tumor size larger than
5 cm, similar to features for malignancy in solitary fibrous tumor.
Metastaticdisease (typicallydisseminatedhematogenously to lung,
liver, and bone) and disease-relatedmortality is extremely rare. At-
tributable to the generally radioresistant nature of MPC, palliative
radiation therapy has been reserved for unresectable and recur-
rent tumor. Chemotherapy has demonstrated limited efficacy and
considered for inoperable tumors or metastases.
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